Zim Laboratories Limited (ZIMLAB) Share Price
NSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE518E01015
Key metrics
- Market Cap
- ₹682 Cr
- P/E Ratio
- 155.34
- EPS
- 0.82
- Book Value
- 55.36
- P/B Ratio
- 2.3
- ROE
- 1.97%
- ROCE
- 2.62%
- Debt / Equity
- 0.43
- Net Margin
- 1.62%
- Revenue Growth
- -0.78%
- Profit Growth
- -52.01%
- Dividend Yield
- —
- 52W High
- ₹133.90
- 52W Low
- ₹59.31
- Market Cap Band
- small cap
- Face Value
- 10
Ratios computed from the annual results period ending 2026-03-31.
About Zim Laboratories Limited
ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, directly compressible granules, tablets, capsules, dry syrup, and oral thin films. The company offers therapeutics in the areas of urology, gastroenterology, antibiotics, anti-infectives, cardiovascular, central nervous system, NSAIDs/pain analgesics, and vitamins and supplements. The company was founded in 1984 and is based in Nagpur, India.
- Headquarters
- Nagpur, India
- Employees
- 632
- Promoter Holding
- 71.23%
The full Zim Laboratories Limited analysis
Create a free account to open the complete ZIMLAB deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.